z-logo
open-access-imgOpen Access
Performance and cost of a renal cancer specialist multidisciplinary team meeting: Results from 1500 discussions
Author(s) -
Neves Joana B,
Shepherd Scott,
Cullen David,
Powles Tom,
Aitchison Michael,
Tran Maxine G B
Publication year - 2019
Publication title -
journal of clinical urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.192
H-Index - 10
eISSN - 2051-4166
pISSN - 2051-4158
DOI - 10.1177/2051415819829309
Subject(s) - medicine , multidisciplinary approach , family medicine , cancer , deferral , multidisciplinary team , nice , quarter (canadian coin) , retrospective cohort study , surgery , nursing , finance , social science , archaeology , sociology , computer science , economics , history , programming language
Objectives: To report on the performance and cost of a surgeon-led renal cancer specialist multidisciplinary team meeting at a high-volume centre.Materials and methods: Retrospective analysis of 1500 consecutive cases discussed from 2 September 2015 onwards. Performance was assessed as the number of cases where a clinical recommendation was made. The cost per meeting, discussion and patient were calculated using the mid-point of pay band attributable to the attendees (National Health Service pay scales 2015).Results: Over 34 meetings, 1500 discussions occurred (933 patients: 61.7% male; mean age 63.8). Above a one-quarter of discussions ( n = 399, 26.6%) were new referrals. Each patient’s case was discussed a mean of 1.6 times, the majority being discussed once ( n = 563, 60.3%). In 93.3% of discussions, a clinical recommendation was made. Only 100 discussions (6.7%) were deferred due to incomplete clinical information. A total of 11.1% ( n = 166) cases were discharged. The average costs were: £141,901 per year, £2729 per meeting, £62 per case discussed and £99 per patient.Conclusion: One discussion was usually sufficient to decide management; deferral was uncommon; and, given the low discharge rate, referrals seemed appropriate. The cost per patient was modest, and represented good value in providing a focused and shared clinical decision-making pathway for renal cancer patients.Level of evidence: 2C

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom